Skip to main content
. Author manuscript; available in PMC: 2022 Mar 11.
Published in final edited form as: Sci Transl Med. 2021 May 19;13(594):eabc1739. doi: 10.1126/scitranslmed.abc1739

Figure 4. De novo evolutionary action score burden and ASD patient IQ for prioritized and deprioritized gene groups.

Figure 4.

Prioritized genes, deprioritized genes, and all genes with de novo missense variants were assessed for their relationship to the IQ of patients with ASD. For each male patient, the summed evolutionary action burden of de novo missense variants was calculated for each category with evolutionary action score weighting for genic intolerance to mutation (∑EAweighted). The patients were then split into three groups by their full-scale IQ score and the scores were compared using Kruskal-Wallis tests. Error bars reflect the 95% CI of the mean.